Balaxi Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Balaxi Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹-144 of operating cash. Lower than 98% of Healthcare companies in India.
- Cash Locked Ratio: For every ₹100 of sales, ₹72 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹36 tied up three years earlier. More money tied up than 98% of Healthcare companies in India.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 96% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹-144Over the last 3 years, every ₹100 of reported profit came with ₹-144 of operating cash.
Lower than 98% of Healthcare companies in India.
Self-Funding Ratio
-0.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 96% of Healthcare companies in India.
Cash Locked Ratio
₹72For every ₹100 of sales, ₹72 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹36 tied up three years earlier.
More money tied up than 98% of Healthcare companies in India.
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 94% of Healthcare companies in India.
Growth Efficiency Ratio
—Sales fell 20%
Sales fell 20% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-20% / +41%In 3 years sales changed by -20% while total assets changed by +41%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-0.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 91% of Healthcare companies in India.
Cash Cushion Ratio
−37%Debt, after subtracting cash, equals 37% of its market value (net debt).
Lower than 96% of Healthcare companies in India.
Tangible Assets Ratio
90%Of every ₹100 the company owns, ₹90 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 70% of Healthcare companies in India.
Tangible Net Worth Ratio
87%Of every ₹100 of net worth, ₹87 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 65% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Balaxi Pharmaceuticals Limited owes ₹0.26 for every ₹1 it owns. Net profit fell 94% in the year to Mar 2026, and shrank 69% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
46.7Investors pay ₹46.7 for every ₹1 of Balaxi Pharmaceuticals Limited's yearly profit, higher than 66% of Healthcare companies in India.
P/B ratio
0.47The share price is 0.47 times Balaxi Pharmaceuticals Limited's book value per share, lower than almost all Healthcare companies in India.
Market cap
₹116 CrThe total market value of all of Balaxi Pharmaceuticals Limited's shares at today's price (share price × number of shares), smaller than 97% of Healthcare companies in India. PosiCap size class: Micro Cap.
Net worth (book value)
₹249 CrWhat Balaxi Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹45.12Net worth divided by the number of shares. The share price of ₹21.00 is 0.5 times this, which is the P/B above.
Return on equity (ROE)
1.0%Balaxi Pharmaceuticals Limited earned 1.0% on its shareholders' money over the last year, lower than 91% of Healthcare companies in India.
Owes vs Owns
0.26×Balaxi Pharmaceuticals Limited owes ₹0.26 for every ₹1 it owns (low), lower than 72% of Healthcare companies in India.
Dividend yield
NoneBalaxi Pharmaceuticals Limited does not currently pay a dividend.
Revenue growth
-8%Revenue fell 8% in the year to Mar 2026, and shrank 7% a year on average over 3 years.
Profit growth
-94%Net profit fell 94% in the year to Mar 2026, and shrank 69% a year on average over 3 years.
Profit margin
0.5%Balaxi Pharmaceuticals Limited keeps ₹1 of every ₹100 of revenue as net profit.
Cash quality
-3.2×Cash from Balaxi Pharmaceuticals Limited's business was -3.2× its reported profit in the year to Mar 2026 — the business used cash even though it reported a profit.
Interest cover
1.9×Balaxi Pharmaceuticals Limited's operating profit covered its interest costs 1.9 times in the year to Mar 2026.
Cash vs debt
Net debtBalaxi Pharmaceuticals Limited had ₹43 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Balaxi Pharmaceuticals Limited's P/E ratio?
Investors pay ₹46.7 for every ₹1 of Balaxi Pharmaceuticals Limited's yearly profit, higher than 66% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Balaxi Pharmaceuticals Limited: ₹116 Cr ÷ ₹249 Cr (31 Mar 2026) = 0.5.
What is Balaxi Pharmaceuticals Limited's return on equity?
Balaxi Pharmaceuticals Limited earned 1.0% on its shareholders' money over the last year, lower than 91% of Healthcare companies in India.
How much does Balaxi Pharmaceuticals Limited owe compared with what it owns?
Balaxi Pharmaceuticals Limited owes ₹0.26 for every ₹1 it owns (low), lower than 72% of Healthcare companies in India.
Does Balaxi Pharmaceuticals Limited pay a dividend?
No. Balaxi Pharmaceuticals Limited does not currently pay a dividend.
Is Balaxi Pharmaceuticals Limited's revenue growing?
Revenue fell 8% in the year to Mar 2026, and shrank 7% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.